CLEVELAND, Ohio – Cell X Technologies’ CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA, who will take on the newly created position of Vice President, Operations. In this role, he will oversee sales, marketing, product development, and product management to drive growth in all cell therapy markets served by Cell X. [Read more…]
Professional Course on Preservation of Cellular Therapies – May 18-19, 2021
Preservation of Cellular Therapies is a professional short course founded in 2003 to provide practical training for those individuals involved in the preservation of cellular therapies. This virtual course is associated with the Biopreservation Core Resource at the University of Minnesota and will be hosted on May 18-19, 2021.
Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA
April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.
The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]
Horizon 2020 consortium funding to fuel cell therapy microcarrier development at denovoMATRIX
DRESDEN, Germany, April 29, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced today that it will participate in the new European collaborative project funded by the European Union’s Horizon 2020 research and innovation program.
Organicell Announces Positive Results Of Initial COVID-19 Zofin™ Patient Trial In India And Trial Expansion
Miami, FL (April 28, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients. [Read more…]
- « Previous Page
- 1
- …
- 167
- 168
- 169
- 170
- 171
- …
- 338
- Next Page »